Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733674) titled 'Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC' on July 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Radiomedix, Inc.
Condition:
Glioblastoma Multiforme (GBM)
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
Drug: 203Pb-RMX-VHPIB injection
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: August 15, 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more...